Acelrx Stock Story

ACRX

Stock

USD 0.32 0.01 3.23%

Macroaxis Story

Today we may see the proof that Adamis Pharmaceuticl would recover much slower from the recent decline as its shares went up 8.57% to Acelrx Pharmaceutica's 16.6667%. While some of us are excited about healthcare space, we will evaluate how strong are Acelrx Pharmaceutica and Adamis Pharmaceuticl fundamentals. We are going to inspect some of the competitive aspects of both Acelrx and Adamis.

Published over three months ago

View all stories for Acelrx Pharmaceutica | View All Stories

Is Adamis more volatile than Acelrx Pharmaceutica (NASDAQ:ACRX)?

By analyzing existing basic indicators between Acelrx Pharmaceutica and Adamis, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Adamis with a short position in Acelrx Pharmaceutica. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Acelrx Pharmaceutica has an asset utilization ratio of 2.78 percent. This suggests that the company is making $0.0278 for each dollar of assets. An increasing asset utilization means that Acelrx Pharmaceutica is more efficient with each dollar of assets it utilizes for everyday operations.

Is Adamis more volatile than Acelrx Pharmaceutica (NASDAQ:ACRX)?

Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Acelrx or Johnson is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Acelrx Pharmaceutica's Liquidity

Acelrx Pharmaceutica financial leverage refers to using borrowed capital as a funding source to finance Acelrx Pharmaceutica ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Acelrx Pharmaceutica financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Acelrx Pharmaceutica's total debt and its cash.

Correlation Between Acelrx and Johnson Johnson

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Acelrx Pharmaceutica together with similar or unrelated positions with a negative correlation. For example, you can also add Johnson Johnson to your portfolio. If Johnson Johnson is not perfectly correlated to Acelrx Pharmaceutica it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Acelrx Pharmaceutica for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.

Please check pair correlation details between ACRX and JNJ for more information.

Acquisition by Bozilenko Marina of 31000 shares of Acelrx Pharmaceutica subject to Rule 16b-3

Legal trades by Acelrx Pharmaceutica insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Acelrx insider trading alert for grant of stock option (right to buy) by Bozilenko Marina, the corporate stakeholder, on 15th of July 2022. This event was filed by Acelrx Pharmaceuticals In with SEC on 2022-07-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now check Acelrx Pharmaceutica revenue. Based on the latest financial disclosure, Acelrx Pharmaceutica reported 3.55 M of revenue. This is 99.95% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 99.96% higher than that of Acelrx Pharmaceutica. As for Adamis Pharmaceuticl we see revenue of 17.8 M, which is much higher than that of the Drug Manufacturers—Specialty & Generic

	Acelrx	3.55 Million
	Sector	0.0
	Adamis	17.8 Million

Acelrx

Sector

17.8 M

Adamis

Are Acelrx Pharmaceutica technical ratios showing a recoup?

Current coefficient of variation indicator falls down to -752.91. Possible price jump? Acelrx Pharmaceutica is displaying above-average volatility over the selected time horizon. Investors should scrutinize Acelrx Pharmaceutica independently to ensure intended market timing strategies are aligned with expectations about Acelrx Pharmaceutica volatility. Acelrx Pharmaceutica is a potential penny stock. Although Acelrx Pharmaceutica may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Acelrx Pharmaceutica. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Acelrx instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Final Take On Acelrx Pharmaceutica

While some firms in the drug manufacturers—specialty & generic industry are either recovering or due for a correction, Acelrx may not be as strong as the others in terms of longer-term growth potentials. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither pick up nor trade any shares of Acelrx Pharmaceutica at this time. The Acelrx Pharmaceutica risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Acelrx Pharmaceutica.

Editorial Staff

Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Acelrx Pharmaceutica. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2022 Macroaxis LLC